ISRCTN ISRCTN11635332
DOI https://doi.org/10.1186/ISRCTN11635332
Sponsor University of Birmingham
Funders Birmingham Women's and Children's NHS Foundation Trust, Investigator initiated and funded
Submission date
02/10/2026
Registration date
07/10/2026
Last edited
07/10/2026
Recruitment status
Recruiting
Overall study status
Ongoing
Condition category
Urological and Genital Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
To fertilize the egg, sperm must accomplish several complicated tasks and only display many of their skills once inside the female genital tract. Activation of motility, swimming at low and high viscosity, navigation, and a particularly intense movement called hyperactivation are all thought to be crucial for natural and at a lesser level, for IVF fertility success.

This means that the detail of how a sperm swims is a key potential diagnostic factor. In this trial the Birmingham team are deploying a novel software system that analyses videos of the sperm observed on the microscope in routine practice for fertility assessment and treatment. The study will then examine whether the detailed AI analysis of the sperm motility can be correlated to the reproductive outcomes for the associated people having treatment. There are no additional interventions in treatment - nothing happens differently to them - but we hope that analysis of the data afterwards will allow us to identify certain critical sperm movement factors that would inform future trials, changing the treatment people received and reducing the chance of inappropriate treatments not working.

The aim is to discover whether newly created software that can measure details of sperm tail beat is a better diagnostic of fertility potential and outcomes than simple sperm counts.

Who can participate?
All individuals undergoing fertility treatments in participating sites that have swimming sperm.

What does the study involve?
There is no change to any treatment or care, video observations of sperm motility in the laboratory prepared sperm will be analysed and compared to the outcomes of treatment.

What are the possible benefits and risks of participating?
No risks or benefits to the participants, but you will be part of a study that may help people in the future.

Where is the study run from?
The study is being led from the Centre for Human Reproductive Science at the University of Birmingham and Birmingham Women’s Hospital (UK).

When is the study starting and how long is it expected to run for?
October 2026 to September 2030.

Who is funding the study?
Birmingham Women's and Children's NHS Foundation Trust (UK).

Who is the main contact?
Professor Jackson Kirkman-Brown, j.kirkmanbrown@bham.ac.uk
Dr Meurig Gallagher, m.t.gallagher@bham.ac.uk

Contact information

Prof Jackson Kirkman-Brown
Principal investigator

Centre for Human Reproductive Science
College of Medicine & Health
The University of Birmingham
Edgbaston
Birmingham
B15 2TT
United Kingdom

ORCiD logoORCID ID 0000-0003-2833-8970
Email j.kirkmanbrown@bham.ac.uk
Dr Meurig Gallagher
Scientific

Centre for Human Reproductive Science
College of Medicine & Health
The University of Birmingham
Edgbaston
Birmingham
B15 2TT
United Kingdom

ORCiD logoORCID ID 0000-0002-6512-4472
Email m.t.gallagher@bham.ac.uk
RESEARCH NURSE
Public

Birmingham Women's Hospital
R&D Gynae Team
Birmingham
B15 2TG
United Kingdom

Phone +44 7469 375 162
Email researchdonor@bham.ac.uk

Study information

Primary study designObservational
Observational study designCase series
Scientific titleMotilitY diagnostics in Insemination – The My-I Project
Study acronymMy-I
Study objectives My-I is a multi-centre, multi-country evaluation of the potential of sperm flagellar movement as a novel prognostic in ART outcome. The primary objective of the clinical project is to determine whether there is a useful prognostic link between flagellar motility where the primary outcome measure is determination of the impact of the intervention on CPR based on detection of fetal heartbeat and/or fetal sac at 6-9 weeks’ gestation.

Secondary objectives will include LBR ≥37 weeks’ gestation, miscarriage rate defined as pregnancy loss after confirmation of clinical pregnancy; and conception or fertilisation rates.
Ethics approval(s)Ethics approval not required
Health condition(s) or problem(s) studiedFertility; infertility; semen analysis; sperm testing
MethodologyNo randomisation will occur in this project, all participants follow the standard care clinical treatment pathway as comparable patients not in the study, just with anonymised post-hoc analysis as outlined in the trial protocol.

The only difference being that My-I will incorporate the analysis of microscopy videos of sperm in existing ART preparations.
Intervention typeOther
Primary outcome measure(s)
  1. Successful fertility treatment measured using Clinical Pregnancy Rate = fetal heartbeat and/or fetal sac at 6-9 weeks’ gestation
  2. Conception rates (biochemical), Live Birth Rate = LBR ≥37 weeks’ gestation or Miscarriage rate (CPR not reaching LBR) measured using patient reported / clinic recorded at ≥37 weeks’ gestation
  3. Laboratory embryology parameters as available measured using fertilisation rates, embryo grade, embryo euploidy (where available), related scores (e.g. by AI where available) at Embryology laboratory Day zero to Day seven
Key secondary outcome measure(s)
Completion date01/09/2030

Eligibility

Participant type(s)
Age groupMixed
Lower age limit18 Years
Upper age limit100 Years
SexAll
Target sample size at registration6000
Key inclusion criteriaMy-I will take data from multiple leading ART assisted conception units across the world. All participating sites will be recognised teaching institutions (or equivalent) accredited in the performance of ART fertility treatments and have been initially selected on the basis of potentially high-quality data provision, with sufficient patient throughput.
1. Couples/individuals able to provide informed consent (where required)
2. Couples/individuals undergoing ART procedure
3. Female:
3.1. Age: 18+ years
4. Male/donor:
4.1. Age: 18+ years
4.2. Motile sperm available for the treatment cycle
4.3. For couples or individuals using donor sperm, consent of the female partner is all that is required (donor consent not required)
4.4. For couples or individuals using donor oocytes, consent of the partner providing the sperm is all that is required (if donor sperm no consent required)
Key exclusion criteriaCouples/individuals who have not consented prior to ART procedure will be ineligible (where consent is required)
Date of first enrolment01/10/2026
Date of final enrolment31/12/2029

Locations

Countries of recruitment

  • United Kingdom
  • England
  • Australia
  • Belgium
  • Greece
  • South Africa

Study participating centre

Birmingham Women's Fertility Centre
Birmingham Women's Hospital
Mendelssohn Drive
Edgbaston
Birmingham
B15 2TG
England

Results and Publications

Individual participant data (IPD) Intention to shareNo

Editorial Notes

07/10/2026: Trial's existence confirmed by NHS HRA.